Sign In
Buy NBIX
$167.35
+2.24 (+1.36%)
At Close: Jun 04, 2026
Neurocrine Biosciences: Disappointing Data From A Key Readout Hits The Stock Hard
01:11pm, Wednesday, 28'th Aug 2024
Neurocrine Biosciences posted disappointing Phase II data for its schizophrenia drug NBI-1117568, driving a steep fall in the share price. NBI-568 came up short in terms of PANSS reduction, with a 7.5
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
11:16am, Wednesday, 28'th Aug 2024
Wednesday, Neurocrine Biosciences, Inc. NBIX topline data for its Phase 2 clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia.
Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
07:07am, Wednesday, 28'th Aug 2024
Tokyo, Japan and Cambridge, UK, 28 August 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes the announcement by
Neurocrine's schizophrenia drug meets main goal in mid-stage study
07:06am, Wednesday, 28'th Aug 2024
Neurocrine Biosciences said on Wednesday its experimental drug to treat adults with schizophrenia met the main goal in a mid-stage study.
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
07:00am, Wednesday, 28'th Aug 2024
The Once-Daily 20 mg Dose Met the Primary Endpoint, Demonstrating a Statistically Significant 7.5-Point Improvement (p=0.011, 0.61 Effect Size) in the PANSS Total Score Compared to Placebo at Week 6 w
Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
04:01pm, Wednesday, 07'th Aug 2024
SAN DIEGO , Aug. 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Canaccord Genuity 44th Annual Growth Conference in Boston at 3:30 p.m. Eastern Time on Wednesda
Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes"
01:46pm, Tuesday, 06'th Aug 2024
Neurocrine (NBIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Neurocrine Biosciences Delivering Strong Core Results, And Significant Pipeline Value Could Be On The Way
10:49am, Friday, 02'nd Aug 2024
Ingrezza sales are on the rise, with a 32% increase in sales in Q2'24, and there is still an attractive runway of growth ahead for the drug. The Phase II results of '845 in major depressive disorder e
Compared to Estimates, Neurocrine (NBIX) Q2 Earnings: A Look at Key Metrics
11:07am, Thursday, 01'st Aug 2024
While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare
Neurocrine Biosciences (NBIX) Lags Q2 Earnings Estimates
09:05am, Thursday, 01'st Aug 2024
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $0.63 per share, missing the Zacks Consensus Estimate of $1.15 per share. This compares to earnings of $0.95 per share a year ago.
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
07:00am, Thursday, 01'st Aug 2024
INGREZZA® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.25 - $2.3 Billio
Insights Into Neurocrine (NBIX) Q2: Wall Street Projections for Key Metrics
10:20am, Wednesday, 31'st Jul 2024
Evaluate the expected performance of Neurocrine (NBIX) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:07am, Thursday, 25'th Jul 2024
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine's Growing Sales, Profits Attracting Big Money
10:35am, Friday, 19'th Jul 2024
Sales and profits have been rocketing upwards for Neurocrine Biosciences, Inc. (NBIX), and a recent regulatory approval should continue that trend.
SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of a new sprinkle formulation of INGREZZA® (valbenazine) capsules, the #1 prescribed
